KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer
Status:
Recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
The study is an interventional Phase II clinical trial aiming to optimize immunotherapy
strategies for microsatellite-stable colorectal cancer. We will include three types of
metastatic colorectal cancer patients: those without liver metastasis, or carrying BRAF V600E
mutation, or unable to tolerate chemotherapy as their initial or second-line treatment. The
participants will receive a combination treatment of regorafenib and KN046 which is a
PD-L1/CTLA-4 bispecific antibody. Treatment efficacy and safety profile would be evaluated in
this study.